6917.TWO Andros Pharmaceuticals Co.,Ltd

Healthcare Biotechnology Taiwan OTC Exchange
29.80 TWD
Close of Nov 6, 2026
20.00 45.95
Market cap
TWD 1.83B
P/E
-
P/B
3.80x
ROE
-10.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 6917.TWO undervalued?

Graham number

The Graham number of Andros Pharmaceuticals Co.,Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Andros Pharmaceuticals Co.,Ltd fundamental analysis

No fundamental analysis for Andros Pharmaceuticals Co.,Ltd yet.

Andros Pharmaceuticals Co.,Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Andros Pharmaceuticals Co.,Ltd

Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment of Osteoarthritis; and siRNA, an anti-sense oligonucleotide and DNA candidate. …

Full company profile